Dr. David Steensma on Midostaurin and its Future Uses in Acute Leukemia
David Steensma, MD, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.
David Steensma, MD, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.
Steensma says that patients who receive midostaurin, or any promising treatment in acute lymphoma, will likely still need to go on to recieve an allogeneic stem cell transplant. He adds that an allogeneic stem cell transplant is still a patient's best bet for immune effects in a tumor.
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
February 4th 2025During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
Read More
